Apr 21, 2022 8:48am EDT NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also treated with Remdesivir and continued to progress
Apr 08, 2022 8:57am EDT NRx Pharmaceuticals' Interim CEO and other Leaders to Present at 21st Annual Needham Virtual Healthcare Conference
Mar 31, 2022 8:17am EDT NRx Pharmaceuticals Provides Business Update and Reports Full Year 2021 Financial Results
Mar 18, 2022 5:00am EDT NRx Pharmaceuticals, Inc. Appoints Ira Strassberg as Chief Financial Officer and Treasurer
Feb 15, 2022 8:32am EST NRx Pharmaceuticals Announces US National Institutes of Health Study of ZYESAMI® (aviptadil) in Critical COVID-19 is Cleared to Complete Full Enrollment
Feb 11, 2022 8:01am EST NRx Reports Remarks by Israel Institute for Biological Research on the future of the BriLife™ Covid-19 Investigational Vaccine
Feb 02, 2022 7:06pm EST NRx Pharmaceuticals Announces Closing of $25 Million Private Placement Priced at a Premium to Market Under Nasdaq Rules
